IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells

Journal of Clinical Investigation

Volumn 110, Issue 7, 2002, Pages 983-992

  Parihar, Robin ^a   Dierksheide, Julie ^a   Hu, Yan ^a   Carson, William E ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR; MONOCLONAL ANTIBODY;

ARTICLE; CARCINOGENESIS; CELL MEDIATED CYTOTOXICITY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MONOCYTE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR CELL; TUMOR IMMUNITY;

EID: 0036791488     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0215950     Document Type: Article

References (59)

1. Ross, J.S., and Fletcher, J.A. 1998. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells. 16:413-428.
2. Revillion, F., Bonneterre, J., and Peyrat, J.P. 1998. ERB-B2 oncogene in human breast cancer and its clinical significance. Eur. J. Cancer. 34:791-808.
3. Orr, M.S., O'Connor, P.M., and Kohn, K.W. 2000. Effects ofc-erbB2 overexpression on the drug sensitivities of normal human epithelial cells. J. Natl. Cancer Inst. 92:987-994.
4. Sarup, J.C., et al. 1991. Characterization of an anti-p18SHER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul. 1:72-82.
5. Stancovski, I., et al. 1991. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc. Nad. Acad. Sci. USA. 88:8691-8695.
6. her2 monoclonal antibody in patients with her2/neu-overexpressing metastatic breast cancer. J Clin. Oncol. 14:737-744.
7. Pegram, M.D., et al. 1998. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p18SHER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16:2659-2671.
8. Baselga, J., and Albanell, J. 2001. Mechanisms of action of anti-HER2 monoclonal antibodies. Ann. Oncol. 12:S35-S41.
9. Sliwkowski, M.X., et al. 1999. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. 26:60-70.
10. Clynes, R.A., Towers, T.L., Presta, L.G., and Ravetch, J.V. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6:443-446.
11. Robertson, M.J., and Ritz, J. 1990. Biology and relevance of human natural killer cells. Blood. 76:2421-2438
12. Carson, W.E., et al. 2001. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur. J. Immunol. 31:3016-3025.
13. Lieberman, M.D., Sigal, R.K., Williams, N.N., and Daly, J.M. 1991. Natural killer cell stimularory factor (NKSF) augments natural killer cell antibody-dependent tumoricidal response against colon carcinoma cell lines. J. Surg. Res. 50:410-415.
14. Gately, M.K., et al. 1998. The interleukin-12/interleukin-12 receptor system: role in normal and pathologic immune responses. Ann. Rev. Immunol. 16:495-521.
15. Tannenbaum, C.S., et al. 1996. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J. Immunol. 156:693-699.
16. Halcheur, N., et al. 2000. Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients. Clin Exp. Immunol. 119:28-37.
17. Nanni, P., et al. 2001. Combined allogeneic tumor cell vaccination and systemic IL-12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J. Exp. Med. 194:1195-1205.
18. Chen, Y., et al. 2001. Induction of ErbB2/neu-specific protective and therapeutic anti-tumor immunity using genetically modified dendritic cells: enhanced efficacy by co-transduction of gene encoding IL-12. Gene Ther. 8:316-323.
19. Yao, L., et al. 1999. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood. 93:1612-1621.
20. HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 89:4285-4289.
21. Jones, R.G., and Landon, J. 2002. Enhanced pepsin digestion: a novel process for purifying antibody F(ab′)2 fragments in high yield from serum. J. Immunol. Methods. 263:57-74.
22. Liu, Y., el-Ashry, D., Chen, D., Ding, I.Y., and Kern, F.G. 1995. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res. Treat. 34:97-117.
23. Penichet, M.L., et al. 1999. In vivo properties of three human HER2/neuexpressing murine cell lines in immunocompetent mice. Lab. Anim. Sci. 49:179-188.
24. Thierfelder, W.E., et al. 1996. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature. 382:171-174.
25. Carson, W.E., et al. 1994. Interleukin-15 is a novel cytokine which activates human natural killer cells via components of the interleukin-2 receptor. J. Exp. Med. 180:1395-1403.
26. Andersen, B.L., et al. 1998 Stress and immune responses after surgical treatment for regional breast cancer. J. Natl. Cancer Inst. 90:30-36.
27. Scott, S.D. 1998. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. Cancer Pract. 6:195-197
28. Oliver, J.M., Burg, D.L., Wilson, B.S., McLaughlin, J.L., and Geahlen, R.L. 1994. Inhibition of mast cell Fc epsilon R1-mediated signaling and effector function by the Syk-selective inhibitor, piceatannol. J. Biol. Chem. 269:29697-29703.
29. Cooper, M.A., Fehniger, T.A., and Caligiuri, M.A. 2001. The biology of human natural killer-cell subsets. Trends Immunol. 22:633-640.
30. 2+ mobilization and phosphoinositide turnover in human natural killer cells. Role of Ca2+ in Fc gamma(CD16)-induced transcription and expression oflymphokine genes. J. Exp. Med. 169:549-567.
31. Sahin, U., Kraft-Bauer, S., Ohnesorge, S., Pfreundschuh, M., and Renner, C. 1996. Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors. Cancer Immunol. Immunother. 42:9-14.
32. Aste-Amezaga, M., D'Andrea, A., Kubin, M., and Trinchieri, G. 1994. Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells. Cell. Immunol. 156:480-492.
33. Bonnema, J.D., et al. 1994 Cytokine-enhanced NK cell-mediated cytotoxicity: positive modulatory effects of IL-2 and IL-12 on stimulus-dependent granule exocytosis. J. Immunol. 152:2098-2104.
34. Ortaldo, J.R., Mason, A.T., and O'Shea, J.J. 1995. Receptor-induced death in human natural killer cells: involvement of CD16. J. Exp. Med. 181:339-344.
35. Gobin, S.J., and van den Elsen, P.J. 2000. Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F and HLA-G. Hum. Immunol. 61:1102-1107.
36. Yoon, S.J., et al. 1998. Synergistic anti-tumor effects with co-expression of GM-CSF and IFN-gamma in tumors. Int. J. Cancer. 77:907-912.
37. Prevost-Blondel, A., Roth, E., Rosenthal, F.M., and Pricher, H. 2000. Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lew carcinoma cells in vivo. J. Immunol. 164:3645-3651.
38. Walker, W., Aste-Amezaga, M., Kastelein, R.A., Trinchieri, G., and Hunter, C.A. 1999. IL-18 and CD28 use distinct molecular mechanisms to enhance NK cell production of IL-12-induced IFN-gamma. J. Immunol. 162:5894-5901.
39. Cheung, J.C., Koh, C.Y., Gordon, B.E., Wilder, J. A., and Yuan, D. 1999 The mechanism of activation of NK-cell IFN-gamma production by ligation of CD28. Mol. Immunol. 36:361-372.
40. Ting, A.T., et al. 1995. Interaction between Ick and syk family tyrosine kinases in Fc gamma receptor-initiated activation of natural killer cells. J. Biol. Chem. 270:16415-16421.
41. Pignata, C., et al. 1995. Phosphorylation of src family Ick tyrosine kinase following interleukin-12 activation of human natural killer cells. Cell. Immunol. 165:211-216.
42. Manciulea, M., et al. 1996. Divergent phosphotyrosine signaling via FcγRIIIA on human NK cells. Cell. Immunol. 167:63-71.
43. Yoshida, A., et al. 2001. IL-18-induced expression of intercellular adhesion molecule-1 in human monocytes: involvement in IL-12 and IFN-gamma production in PBMC. Cell. Immunol. 210:106-115.
44. Tominaga, K., et al. 2000. IL-12 synergizes with IL-18 or IL-lbeta for IFN-gamma production from human T cells. Int. Immunol. 12:151-160.
45. Skok, J., Poudrier, J., and Gray, D. 1999. Dendritic cell-derived IL-12 promotes B cell induction of Th2 differentiation: a feedback regulation of Th1 development. J. Immunol. 163:4284-4291.
46. Amakata, Y., et al. 2001. Mechanism of NK cell activation induced by coculture with dendritic cells derived from peripheral blood monocytes. Clin. Exp. Immunol. 124:214-222.
47. Chace, J.H., Hooker, N.A., Mildenstein, K.L., Krieg, A.M., and Cowdery, J.S. 1997. Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin. Immunol. Immunopathol. 84:185-193.
48. Rodriguez-Calvillo, M., et al. 2002. Upregulation of natural killer cells functions underlies the efficacy of intratumorally injected dendritic cells engineered to produce interteukin-12. Exp. Hematol. 30: 195-204.
49. van Ojik, H.H., Repp, R., Groenewegen, G., Valerius, T., and van de Winkel, J.G. 1997. Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc gamma RI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer. Cancer Immunol. Immunother. 45:207-209.
50. Fleming, G.F., et al. 1999. A phase I CALGB trial of recombinant human anti-HER2 monoclonal antibody plus low-dose interleukin2 in solid tumors. Proc. Am. Soc. Clin. Oncol. 18:184a. (Abstr. 710)
51. Shalaby, M.R., et al. 1992. Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. J. Exp. Med. 175:217-225.
52. Weiner, L.M., et al. 1995. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res. 55:4586-4593.
53. Valone, F.H., et al. 1995. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J. Clin. Oncol. 13:2281-2292.
54. Gerstmayer, B., Hoffmann, M., Altenschmidt, U., and Wels, W. 1997. Costimulation of T-cell proliferation by a chimeric B7-antibody fusion protein. Cancer Immunol. Immunother. 45:156-158.
55. Penichet, M.L., Dela Cruz, J.S., Shin, S.U., and Morrison, S.L. 2001. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. Hum. Antibodies. 10:43-49.
56. Dela Cruz, J.S., Trinh, K.R., Morrison, S.L., and Penichet, M.L. 2000. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity. J. Immunol. 165:5112-5121.
57. Peng, L.S., Penichet, M.L., and Morrison, S.L. 1999. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J. Immunol. 163:250-258.
58. Cavallo, F., et al. 1999. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin-12. Cancer Res. 59:414-421.
59. Parihar, R. et al. 2001. A phase I trial of Herceptin and interleukin-12 in patients with HER2-overexpressing malignancies. Proc. Am. Soc. Clin. Oncol. 20:258a. (Abstr. 1031)